Retroviral vectors derived from amphotropic murine leukemia viruses (MLV) mediate gene transfer into almost all human cells and are thus not suitable for in vivo applications in gene therapy in which cell-specific gene delivery is required. We and others recently reported the generation of MLV-derived vectors pseudotyped by variants of the envelope glycoproteins (Env) of human immunodeficiency virus type 1 (HIV-1), thus displaying the CD4-dependent tropism of the parental lentivirus (Mammano et al., 1997, J. Virol. 71, 3341-3345; Schnierle et al., 1997, Proc. Natl. Acad. Sci. USA 76, 8640-8645). However, because of their HIV-1-derived envelopes these vectors are neutralized by HIV-specific antibodies present in some infected patients. To circumvent this problem, we pseudotyped MLV capsid particles with variants of Env proteins derived from the apathogenic simian immunodeficiency virus (SIVagm) of African green monkeys (AGM; Chlorocebus pygerythrus). Truncation of the C-terminal domain of the transmembrane protein was found to be necessary to allow formation of infectious pseudotype vectors. These [MLV(SIVagm)] vectors efficiently transduced various human CD4-expressing cell lines using the coreceptors CCR5 and Bonzo to enter target cells. Moreover, they were resistant to neutralization by antibodies directed against HIV-1. Therefore, [MLV(SIVagm)] vectors will be useful to study the mechanisms of SIVagm cell entry and for the selective gene transfer into CD4ϩ T-cells of AIDS patients.
INTRODUCTION
Selective gene transfer into CD4-expressing human T-cells is necessary for the treatment of a variety of immune dysfunctions, including severe combined immunodeficiency (SCID; Anderson, 1984; Blaese et al., 1995) and AIDS (for review, see Yu et al., 1994; Pomerantz and Trono, 1995) as well as T-cell lymphomas. Retroviral vectors derived from murine leukemia virus (MLV) are suitable for efficient gene transfer into human T-cells, because they mediate chromosomal integration of the delivered expression vector and have a low frequency of genetic recombination or mutation.
In many of the ongoing clinical trials employing retroviruses, the retroviral envelopes have been derived from amphotropic MLV. The surface glycoprotein gp70-SU of amphotropic MLV, which targets the cell surface receptor Ram-1 (Kavanaugh et al., 1994; Kozak et al., 1995; Eiden et al., 1996) , allows infection of almost all human primary cells and is therefore not suitable for gene transfer into a predetermined cell type. Consequently, gene transfer is generally performed ex vivo and involves purification of the target cells, gene transfer in tissue culture, and reinfusion of the genetically modified cells.
MLV-derived retroviral vectors selective for CD4-positive cells have been described previously. We and others (Mammano et al., 1997; Schnierle et al., 1997) pseudotyped MLV capsid particles with the envelope glycoproteins (Env) of human immunodeficiency virus type 1 [MLV(HIV-1)] (Indraccolo et al., 1998) with those of the simian immunodeficiency virus from Rhesus macaques (Macaca mulata; [MLV(SIVmac)]). However, the use of [MLV(HIV-1)] in HIV-seropositive individuals is hampered by the presence of antibodies directed against HIV-1 envelope proteins, which are expected to significantly reduce transduction efficiencies. Although neutralization of [MLV(SIVmac) ] vector particles by HIV-1-specific antibodies was not studied by Indraccolo et al. (1998) , it is known from previous reports that sera from HIV-1-infected individuals cross-react with SIVmac (Blomberg et al., 1990) . In contrast, the simian immunodeficiency virus (SIVagm) from African green monkeys (Chlorocebus pygerythrus) is only poorly neutralized by HIV-1-specific antibodies (Cichutek and Norley, 1993) . Furthermore, while SIVmac is pathogenic not only in its natural host but also in other primates (Simon et al., 1994) and humans (Khabbaz et al., 1994) , SIVagm is apathogenic after natural and experimental infection of African green monkeys and other nonhuman primates (Beer et al., 1998) , making the Env proteins of this virus more favorable for the generation of gene-therapy vectors. The [MLV(HIV-1)] vectors were constructed using the surface envelope protein gp120-SU of a T-cell line adapted HIV-1 variant and a truncated transmembrane protein (TM; reviewed in Adachi et al., 1986; Wilk et al., 1992) . In contrast, no formation of infectious pseudotype vectors was observed using the full-length TM-proteins of HIV-1. Curiously, no C-terminal truncation was reported to be necessary for SIVmac Env incorporation by MLV (Indraccolo et al., 1998) , pointing out considerable differences between the envelope glycoproteins of simian and human immunodeficiency viruses. In addition, Lindemann et al. (1997) have reported that fusion of the Cterminal amino acids of the MLV TM mediated enhanced incorporation of heterologous envelope glycoproteins derived from human spuma retrovirus (HSRV) into MLVbased capsid particles. We therefore wanted to assess whether these C-terminal regions of MLV TM would also support the incorporation of envelope glycoproteins derived from SIVagm into the respective vector particles. The study revealed that truncation of the C-terminal domain of TM of SIVagm is required for the formation of infectious pseudotype vectors. The [MLV(SIVagm)] vectors specifically infected CD4ϩ human cells but, in contrast to [MLV(HIV-1)] vectors, were resistant to HIV-specific antibodies or any other inhibiting factor present in the sera of HIV-1-infected individuals.
RESULTS
Variant env genes of SIVagm are functionally expressed in TELCeB6/rev cells and mediate syncytia formation with CD4ϩ T-cells
The wild-type env gene of SIVagm encodes a 130-kDa surface glycoprotein (gp130-SU) and the transmembrane glycoprotein gp35-TM. Two env gene variants derived from wild-type SIVagm3mc env (Baier et al., 1990) were constructed by C-terminal truncation of TM (see Fig. 1 ). These variants were designed to encode the full-length gp135-SU plus a truncated variant of TM, each comprising a C-tail of 10 (⌬10 env) and 23 (⌬10MLV env) amino acids, respectively, following the putative transmembrane region (TMR). As a result of the cloning strategy, a few additional amino acids unrelated to the wild-type TM were added to the C-termini (see Fig. 1 , amino acids in bold). Env genes ⌬10 env and ⌬10MLV env encode 7 C-terminal amino acids derived from SIVagm and 3 residues generated by a recombinant NotI-restriction site within the respective env gene variant. In addition, ⌬10MLV env includes parts of the MLV env gene to express a chimeric TM-protein terminated by amino acids derived from MLV TM, which presumably allow contact with the capsid proteins of the MLV core. The HIV-1 rev-positive, but env-negative, packaging cell line TELCeB6/rev constitutively producing capsid particles of MLV was used for the initial experiments to ensure sufficient expression of recombinant env gene constructs derived from SIVagm. This new packaging cell line allows efficient expression of rev-negative lentiviral env genes (data not shown).
TELCeB6/rev cells were transfected with plasmid DNA comprising the variant SIVagm env genes described above and cocultivated with Molt4.8 cells. After 3 days, very large syncytia were seen in cultures containing cells expressing ⌬10 env, whereas all other cocultures, including those with wild-type SIVagm Env-positive cells, showed only small syncytia (data not shown). All syncytia observed were specifically stained in the SIVagm-specific immunoperoxidase assay, indicating that they were formed by expression of fusion-competent env gene products. 
SIVagm-derived env gene products encompassing C-terminally truncated TM allow pseudotype formation with MLV
To test [MLV(SIVagm)] particle formation and subsequent marker gene transfer, the cell line TELCeB6/rev was transfected with plasmid DNA encoding the respective SIVagm env gene variants or with plasmid pHIT456 encoding the amphotropic MLV env gene (aMLV env) as a positive control. Twenty-four hours later, the cells were cocultivated with 5 ϫ 10 5 Molt4.8 T-cells in transwell culture plates, which prevent cell-to-cell contact but allow diffusion of vector particles to the target cells. After a further 2 days, the T-cells were expanded separately for an additional 2 days, and then X-gal-stained to detect marker-gene transfer. The transfected packaging cells were also immunostained to quantify the number of cells expressing lentiviral envelope glycoproteins to ensure comparable transfection efficiencies in all experiments.
No gene transfer was detected using the transfected env gene construct pRepwt env or the negative control cells (Fig. 2) . In contrast, efficient gene transfer was detectable following transfection of env gene variants ⌬10 env and ⌬10MLV env, presumably as a result of infectious pseudotype particle formation. The number of transduced cells, and thus the titer of [MLV(SIVagm)] particles formed, using ⌬10 Env (650 transduced cells) was similar to that seen using amphotropic MLV Env (720 transduced cells). Addition of the C-terminal amino acid sequences of MLV in construct pRep⌬10MLV env led to a decrease in infectious particle formation relative to that observed using the env gene variant ⌬10 env.
[MLV(SIVagm)] vector particles specifically infect CD4ϩ cells, efficiently utilizing the coreceptors CCR5 and Bonzo
To establish a packaging cell line continuously producing [MLV(SIVagm)] vector particles, plasmid pRep⌬10 env, containing in addition to the SIVagm env gene variant a hygromycin resistance gene, was transfected into TELCeB6 cells. Following hygromycin B selection, more than 50 resistant cell colonies were randomly selected and shown by immunostaining to express the SIVagm env gene. These colonies were pooled and expanded further to give the packaging cell line ⌬10Mix. Using anti-SIVagm serum and a protein G-gold-labeled conjugate, labeled vector particles derived from ⌬10Mix cells were seen by electron microscopy (data not shown), indicating the presence of SIVagm-derived envelope glycoproteins. Neither the parental env-negative packaging cell line TELCeB6 nor TELCeB6 cells transiently transfected with pHIT456 DNA (encoding the amphotropic MLV env gene) produced particles stained with this procedure (data not shown).
These [MLV(SIVagm)] vector stocks harvested from ⌬10Mix packaging cells were employed to transduce the human T-cell lines Molt4.8, C8166, and Jurkat as well as HeLa and HeLaCD4ϩ cells. All CD4-positive human cells were transduced by [MLV(SIVagm)] vector particles (Fig. 3) . Titers in Molt4.8 and C8166 cells were 8 and 5 ϫ 10 4 i.u./ml, respectively. Titers 2-4 were orders of magnitude lower in Jurkat and HeLaCD4ϩ cells, while no transduction of CD4-negative HeLa cells was detected. particles was CD4-dependent, transduction experiments were performed in Molt 4.8 cells in the presence of the monoclonal anti-CD4 antibody IOT4a, previously shown to inhibit HIV-1 infection (Sattentau et al., 1986) . Target cells were preincubated for 30 min with the antibody before [MLV(SIVagm)] vector particles were added. After 2 h, cells were washed and expanded for 3 days.Vector titers were then measured by X-gal staining. As shown in Fig. 4A , IOT4a dose-dependent inhibition of transduction was observed. In contrast, no influence on the gene transfer efficacy was detectable in the presence of 5 g/ml of the control antibodies, directed against the nerve growth factor receptor and CD3, respectively (data not shown). Entry of the [MLV(SIVagm)] vector particles, therefore, depends on the presence and availability of the human CD4 receptor.
To elucidate the coreceptor dependence of the [MLV-(SIVagm)] vectors, two panels of cell lines (U87 and GHOST), each expressing human CD4 alone or CD4 plus one of several coreceptors described to allow cell entry of various HIV and SIV strains, were tested (Hill et al., 1997; Cecilia et al., 1998) MLV-(SIVagm) ] vector-containing supernatant harvested from the packaging cell line ⌬10Mix and vector titers were measured 2 days later. For both cell panels, the most efficient transduction was observed with cells expressing CD4 and the coreceptor CCR5 (Fig. 4B) . GHOST cells expressing Bonzo were also transduced, however, significantly less efficiently. Besides CCR5, the coreceptors Bob and Bonzo were shown to be used by various other SIV strains . It is noteworthy that all other U87 and GHOST cells, even those expressing only CD4, showed evidence of low-level transduction. For the GHOST-cell panel, a low level of Bonzo background expression was recently demonstrated by Edinger et al. (1998) . As revealed by RT-PCR on RNA extracted from the U87 cell variants, we could detect Bob-and Bonzospecific mRNA (data not shown). Thus, the low level of background transduction was probably due to Bonzo expression. Overall, CCR5 and Bonzo are the coreceptors used by the [MLV(SIVagm)] vectors. Similar coreceptor usage was observed during infection of U87 and GHOST cells with replication-competent SIVagm3mc (data not shown).
[MLV(SIVagm)] pseudotype vectors are resistant to neutralization by sera from HIV-1 infected individuals
SIVagm are only poorly neutralized by anti-HIV-1 antibodies (Cichutek and Norley, 1993) and to test whether [MLV(SIVagm)] vector particles are also unaffected, transduction experiments were performed in the presence of sera from asymptomatic HIV-1-infected donors previously shown to neutralize various T-cell line adapted and primary isolates of HIV-1: 5 ϫ 10 3 i.u. of [MLV(SIVagm)] and of [MLV(HIV-1)] (Stitz et al., 1998) were used to transduce Molt4.8 T-cells after incubation with the sera (diluted 1:20) for 1 h at 37°C. Two days later, as shown in Fig. 5 , X-gal staining revealed that the titers of both pseudotyped vectors were slightly decreased by serum from a healthy donor (control serum). In contrast, anti-HIV-1 sera drastically reduced the titer of the [MLV(HIV-1)] vector particles, whereas no significant effect on the [MLV(SIVagm)] vector was seen.
DISCUSSION
Here we report that the gene products of SIVagm env gene variants encoding C-tails of 10 and 23 amino acids enabled formation of infectious [MLV(SIVagm)] vector particles. In contrast, the wild-type Env of SIVagm, comprising 144 C-terminal amino acids, was unable to mediate infectivity to MLV capsid particles. Curiously, Indraccolo and his coworkers (1998) described comparable vector titers using the unmodified wild-type and a C-terminally truncated variant of SIVmac Env protein, respectively. Possibly, the three-dimensional structure of the C-terminal domain of the SIVmac TM protein differs from that of the SIVagm and HIV-1 TM proteins and is therefore more easily incorporated into the MLV capsid particles. An unexpected finding of our experiments was that adding the C-terminal amino acids derived from TM of amphotropic MLV to the truncated SIVagm TM C-tail did not increase vector titers but even reduced them about fivefold. From studies on HIV-1 assembly, it is known that contact between the C-tail of Env and the capsid facilitates incorporation of Env proteins (Andreassen et al., 1992; Yu et al., 1992; Bugelski et al., 1995; Egan et al., 1996; Lee et al., 1997) and Lindemann et al. (1997) demonstrated that the fusion of MLV-derived C-tails to the Env proteins of human spuma retrovirus (HSRV) significantly enhanced the efficiency of infectious pseudotype vector formation. It is a matter of speculation that these contradictory findings might result from differences in the tertiary structure of HSRV-TM and SIVagm3-TM. Further constructs need to be tested to resolve this difference.
Alternatively, the enhanced ability of variant ⌬10 Env to induce large syncytia as compared to ⌬10MLV Env, might explain its higher infectivity. The increase of the fusion ability of lentiviral Env proteins by truncation of the TM C-terminus was demonstrated before. HIV-1 Env gene variant Tr712 was used for the production of infectious [MLV(HIV-1)] vector particles (Wilk et al., 1992; Schnierle et al., 1997) . Similarly, Zingler and Littman (1993) observed enhanced infectivity of SIVmac239 pseudotyped with C-terminally truncated Env-variants compared to wild-type envelope glycoproteins. In addition, the increase of the fusion capability of MLV Env by truncating the C-tails during virion maturation is well characterized (Rein et al., 1994) .
Using the Env variant ⌬10 Env, we established a stable pseudotype packaging cell line termed ⌬10Mix to generate [(MLV(SIVagm)] pseudotype vector stocks. The [MLV(SIVagm)]-pseudotyped vectors allowed efficient transduction of human T-cells with titers of up to 8 ϫ 10 4 i.u./ml. In contrast, [MLV(SIVmac)] pseudotype vector particles (Indraccolo et al., 1998) were described to be less efficient, yielding maximum titers of 3 ϫ 10 3 i.u./ml. More important, and in contrast to [MLV(HIV-1)] vector particles, the [MLV(SIVagm)] vectors were demonstrated to be resistant to neutralization by sera from HIV-1-infected individuals, most likely due to the resistance against neutralizing HIV-1-specific antibodies.
Transduction mediated by the [MLV(SIVagm)] pseudotype vectors was shown to be CD4-dependent by inhibition of vector-mediated gene transfer in the presence of CD4-specific antibodies. Like SIVagm3mc itself (data not shown), [MLV(SIVagm) ] vector particles were demonstrated to efficiently use the coreceptors CCR5 and Bonzo. CD4 and CCR5 are expressed on human primary T-cells and macrophages (Alkhabit et al., 1996; Deng et al., 1996; Raport et al., 1996; Samson et al., 1996) and are used by HIV-1 for host cell entry (Alkhabit et al., 1996; Choe et al., 1996; Dragic et al., 1996; Raport et al., 1996) . Besides macrophages, CD4ϩ/CCR5ϩ T-cells are believed to function as the natural host cell reservoir for M-tropic HIV-1 strains that are responsible for the initial infection in humans. Therefore, [MLV(SIVagm)] vector particles may be useful for transduction of human CD4ϩ/ CCR5ϩ T-cells with therapeutic genes encoding HIVspecific ribozymes, intrabodies, or antisense RNA (Yu et al., 1994) . Efforts will be made to test the new vectors for their ability to transduce primary human and primate CD4ϩ cells and to establish more efficient packaging cells as a prelude to further studies in vivo. In addition, SIVagm Env variants are currently developed to allow the generation of [MLV(SIVagm)] vectors specific for CD4ϩ/ CXCR4ϩ cells. The resistance of such vectors to neutralization by sera from HIV-1-infected donors may make them ideal vehicles for specific therapeutic gene transfer in HIV-1-infected patients, offering new possibilities for in vivo gene therapy against HIV infection and AIDS.
MATERIALS AND METHODS

Plasmid constructs
Plasmids were purified from transformed Escherichia coli strain Top 10FЈ. The env gene variants of SIVagm3mc were generated using standard PCR and fusion-PCR techniques (Sambrook, 1989) and were inserted into the multiple cloning site of plasmid pRep 4 (Invitrogen, Leek, Netherlands) via NheI/XhoI. Env gene expression is facilitated by the 3ЈLTR of RSV (Rous sarcoma virus) and a polyadenylation signal derived from simian virus 40 (SV40). (Primer-sequences are available on request.) The plasmid pRepwt env encompasses the entire complement of rev and env genes of SIVagm3mc (Baier et al., 1990; Dittmar et al., 1995) . The plasmid pRep⌬10 env is identical to pRepwt env, except that the intracellular domain (C-tail) of the transmembrane protein (TM) is truncated to a total extent of 10 amino acid residues. This was achieved by recombinant PCR, inserting a recombinant NotI-restriction site followed by a stop codon. The plasmid pRep⌬10MLV env was generated by inserting sequences encoding parts of the C-tail of MLV into the recombinant NotI-restriction site. The amino acid sequences of the C-tails encoded by the plasmids mentioned earlier are shown in Fig. 1 . The plasmid pHIT456 encoding the env gene of amphotropic MLV (aMLV env, kindly provided by A. J. Kingsman; University of Oxford, Cambridge, U.K.) has been described elsewhere (Soneoka et al., 1995) .
Cell lines
The T-cell lines Molt4.8, C8166 and Jurkat were grown in RPMI 1640 medium containing 10% fetal calf serum (FCS). The adherent cell lines HeLa, HeLaCD4ϩ (ADP047; reviewed in Chesebro et al., 1991) , and the derivatives of U87 and GHOST (both cell line panels provided by D. Littmann, New York University Medical Center, New York; reviewed in Hill et al., 1997; Cecilia et al., 1998) , as well as the packaging cell lines TELCeB6 (kindly given by Y. Takeuchi and F.-L. Cosset, Chester Beatty Laboratories, London, U.K., reviewed in Cosset et al., 1995) and TELCeB6/rev, were grown in Dulbecco's Modified Eagles Medium (DMEM; GIBCO/BRL, Eggenstein, Germany) supplemented with 10% FCS (GIBCO/ BRL).
The env-negative packaging cell line TELCeB6 (Cosset et al., 1995) , providing the gag/pol gene products of MLV in trans and expressing a -positive, ␤-Gal-encoding expression vector, was employed to generate pseudotype vector particles, because this cell line constitutively releases a large amount of MLV core particles. The cell line TELCeB6/rev is a cell clone derived from TELCeB6 cells, which additionally expresses the rev-gene of HIV-1 (construct pCMV-rev/ hyg; reviewed in Stitz et al., 1998) . Transfections of the packaging cell lines TELCeB6/rev and TELCeB6 were performed employing Lipofectamine (GIBCO/BRL), according to the manufacturer's instructions. Selection of hygromycin-resistant colonies after transfection of the plasmids derived from pRep 4 was carried out in medium containing 200 g/ml hygromycin B (Sigma, Deisenhofen, Germany).
Expression and membrane fusion capacity of the SIVagm envelope glycoproteins
TELCeB6/rev cells were transfected with the plasmids encoding the recombinant env genes of SIVagm3mc. On the following day, the transfected packaging cells were overlaid with Molt4.8 T-cells and cocultivated for 2 days. Cultures were then incubated with ice-cold methanol for 15 min. After repeated washing with PBS, blocking buffer (PBS/1% BSA) was added for 1 h. Cells were then washed again and incubated with an anti-SIVagm serum diluted 1:400 (Nem 170). After further washing, cells were incubated with peroxidase-conjugated protein-G (Biorad, Krefeld, Germany). Finally, antigen-containing cells were visualized by addition of substrate buffer as described previously (Schnierle et al., 1997) .
Cocultivation experiments
TELCeB6/rev cells were seeded in double-chamber six-well tissue culture dishes (Transwell, Costar, Cambridge, MA) and transfected with the respective plasmids. Two days posttransfection, Molt4.8 cells were added to the upper chamber, allowing the free diffusion of vector particles but preventing cell-to-cell contact between the packaging cells and target T-cells. After 2 days, Molt4.8 cells were separated from the transfected packaging cells and expanded for a further 2 days. Transduced T-cells were then stained using the X-gal assay as described elsewhere (Sanes et al., 1986) .
Viral infection, determination of titers, and neutralization experiments
Adherent target cells were seeded in six-well culture dishes at a density of 2 ϫ 10 5 cells/well and T-cells at 1 ϫ 10 6 cells/well. Serial dilutions of cell-free (0.45 m, filtered) vector containing supernatants were added, incubated for 2 h, and washed off. After 2 days, the cells were tested for ␤-Gal activity, stained cells were counted, and viral titers expressed as infectious units per milliliter (i.u./ml). To demonstrate that vector entry into the target cells was mediated by specific binding of the pseudotype vector particles to the cellular receptor CD4, transduction of permissive T-cells was performed in the presence of the neutralizing (Sattentau et al., 1986) CD4-specific monoclonal antibody IOT4a (Dianova, Hamburg, Germany), antibodies directed against the human nerve growth factor receptor (␣NGFR; Boehringer, Mannheim, Germany), and CD3 (OKT-3; OrthoDiagnostics, Germany), respectively. Susceptibility to neutralization by sera from HIV-1-infected donors was tested byincubating 5 ϫ 10 3 i.u. vector particles with or without sera (diluted 1:20) from HIV-1-infected or uninfected donors for 1 h at 37°C in a total volume of 1 ml. Samples were then used to transduce Molt4.8 T-cells as described. Vector titers were estimated after X-gal staining of transduced cells.
